About the centre

The centre was established by a generous donation from Stiftelsen Kristian Gerhard Jebsen.

Organization

The Center director is professor Johanna Olweus.

Strategic research decisions will be made by the Steering Committee consisting of the 6 PIs. A Board consisting of representatives elected on behalf of the institutional partners represents the formal governing body. The Director will, in cooperation with a Management Group that includes two additional members, oversee the daily management of the Center. 

Steering committee/Group leaders

  • Professor Johanna Olweus (head), Dept. of Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet and University of Oslo
  • Professor Karl Johan Malmberg (deputy head), Dept. of Immunology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet and University of Oslo
  • Senior Consultant dr. med Arne Kolstad, Department of Oncology Oslo University Hospital-Radiumhospitalet
  • Professor Kjetil Tasken, Centre for Molecular Medicine Norway, Nordic EMBL Partnership and Biotechnology Centre, University of Oslo and Dept. of Infectious Diseases, Oslo University Hospital
  • Research scientist Fridtjof Lund-Johansen, Department of Immunology, Oslo University Hospital-Rikshospitalet
  • Professor Ton Schumacher, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Localization

Two of the partners belong to the host institution of University of Oslo (KT, JO), four are located at Oslo University Hospital (JO, KJM, FLJ, AK), whereas affiliated partner TS is located at the Netherlands Cancer Institute. Thus, the main focus is in Oslo. However, access to special facilities or resources on each site that give the consortium a competitive edge preclude co-localization. This includes i) large groups of lymphoma patients (AK) for clinical studies, ii) biobanks (AK, JO, FLJ), iii) the Depts of Cellular Therapy and Clinical Cancer Research for unique competence in conducting experimental clinical immunotherapy trials (AK, JO, KJM), and iv) access to frontline technologies developed at The Netherlands Cancer Institute and the Biotechnology Centre of Oslo.

Published Feb. 26, 2013 3:51 PM - Last modified Jan. 16, 2017 11:27 AM